Biocon Ltd vs Concord Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Biocon Ltd is ₹ 359.55 as of 30 Apr 15:30 . The P/E Ratio of Biocon Ltd changed from 62 on March 2022 to 66.3 on March 2021 . This represents a CAGR of 1.35% over 5 yearsThe P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Biocon Ltd changed from ₹ 40166 crore on March 2022 to ₹ 49056 crore on March 2021 . This represents a CAGR of 4.08% over 5 yearsThe Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Biocon Ltd for the Dec '25 is ₹ 4290 crore as compare to the Sep '25 revenue of ₹ 4388 crore. This represent the decline of -2.24% The revenue of Concord Drugs Ltd for the Dec '25 is ₹ 16.99 crore as compare to the Sep '25 revenue of ₹ 10.28 crore. This represent the growth of 65.27% The ebitda of Biocon Ltd for the Dec '25 is ₹ 657.4 crore as compare to the Sep '25 ebitda of ₹ 916.5 crore. This represent the decline of -28.27% The ebitda of Concord Drugs Ltd for the Dec '25 is ₹ 0.94 crore as compare to the Sep '25 ebitda of ₹ 1.1 crore. This represent the decline of -14.55% The net profit of Biocon Ltd changed from ₹ 861.8 crore to ₹ -51.8 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0.22 crore over 7 quarters. This represents a CAGR of 212.22% The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Biocon Ltd

Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.
Also in the same year, the company had received US funding for proprietary technologies.

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

FAQs for the comparison of Biocon Ltd and Concord Drugs Ltd

Which company has a larger market capitalization, Biocon Ltd or Concord Drugs Ltd?

Market cap of Biocon Ltd is 58,279 Cr while Market cap of Concord Drugs Ltd is 112 Cr

What are the key factors driving the stock performance of Biocon Ltd and Concord Drugs Ltd?

The stock performance of Biocon Ltd and Concord Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Concord Drugs Ltd?

As of May 3, 2026, the Biocon Ltd stock price is INR ₹359.55. On the other hand, Concord Drugs Ltd stock price is INR ₹85.13.

How do dividend payouts of Biocon Ltd and Concord Drugs Ltd compare?

To compare the dividend payouts of Biocon Ltd and Concord Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.